Morgan Stanley increased its stake in shares of Sinovac Biotech, Ltd. (NASDAQ:SVA) by 86,309.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,721,912 shares of the biopharmaceutical company’s stock after buying an additional 2,718,762 shares during the period. Morgan Stanley’s holdings in Sinovac Biotech were worth $15,597,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in the stock. Renaissance Technologies LLC raised its position in Sinovac Biotech by 3.4% in the fourth quarter. Renaissance Technologies LLC now owns 1,524,800 shares of the biopharmaceutical company’s stock worth $8,996,000 after buying an additional 49,800 shares in the last quarter. Two Sigma Investments LP raised its position in Sinovac Biotech by 27.2% in the fourth quarter. Two Sigma Investments LP now owns 116,122 shares of the biopharmaceutical company’s stock worth $685,000 after buying an additional 24,821 shares in the last quarter. Spark Investment Management LLC raised its position in Sinovac Biotech by 62.5% in the first quarter. Spark Investment Management LLC now owns 54,600 shares of the biopharmaceutical company’s stock worth $312,000 after buying an additional 21,000 shares in the last quarter. Finally, Verity Asset Management Inc. acquired a new position in Sinovac Biotech during the first quarter worth about $158,000. 37.93% of the stock is owned by hedge funds and other institutional investors.

Sinovac Biotech, Ltd. (NASDAQ SVA) opened at 6.85 on Tuesday. The stock’s market capitalization is $390.23 million. The firm’s 50-day moving average is $5.39 and its 200-day moving average is $5.65. Sinovac Biotech, Ltd. has a 52-week low of $4.60 and a 52-week high of $6.94.

TRADEMARK VIOLATION WARNING: “Sinovac Biotech, Ltd. (NASDAQ:SVA) Stake Increased by Morgan Stanley” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.watchlistnews.com/sinovac-biotech-ltd-nasdaqsva-stake-increased-by-morgan-stanley/1448041.html.

Separately, ValuEngine raised shares of Sinovac Biotech from a “sell” rating to a “hold” rating in a research report on Friday, June 30th.

Sinovac Biotech Company Profile

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.

Want to see what other hedge funds are holding SVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sinovac Biotech, Ltd. (NASDAQ:SVA).

Institutional Ownership by Quarter for Sinovac Biotech (NASDAQ:SVA)

Receive News & Ratings for Sinovac Biotech Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.